Glen J Pearson

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes
    G J Pearson
    Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    J Clin Pharm Ther 26:351-61. 2001
  2. ncbi Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience
    Glen J Pearson
    Department of Medicine, Divisions of Cardiology, Cardiovascular Risk Reduction Clinic, University of Alberta Hospital, Edmonton, Alberta, Canada
    Vasc Health Risk Manag 4:1127-35. 2008
  3. ncbi The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
    Glen J Pearson
    Division of Cardiology, University of Alberta, Edmonton, Canada
    Can J Cardiol 22:939-45. 2006
  4. ncbi Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review
    Dalyce M Zuk
    Department of Medicine, University of Alberta, Edmonton, AB T6G2B7, Canada
    Transplant Rev (Orlando) 23:171-7. 2009
  5. ncbi 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    Todd J Anderson
    Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada
    Can J Cardiol 29:151-67. 2013
  6. ncbi New advances in antirejection therapy
    Michael Chan
    Heart Transplant Program, University of Alberta Hospitals, Edmonton, Alberta, Canada
    Curr Opin Cardiol 22:117-22. 2007
  7. ncbi Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
    Taha H Taher
    Department of Medicine, Edmonton, Alberta, Canada
    Am J Cardiol 89:390-4. 2002
  8. ncbi Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient
    Jeffrey R Burton
    Faculty of Medicine and Dentistry, Division of Cardiology, University of Alberta, Edmonton, AB, Canada
    Ann Pharmacother 41:133-7. 2007
  9. ncbi Supratherapeutic response to ezetimibe administered with cyclosporine
    Sheri L Koshman
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Ann Pharmacother 39:1561-5. 2005
  10. ncbi Use of OTC and herbal products in patients with cardiovascular disease
    Chantal Pharand
    Faculty of Pharmacy, Université de Montréal and Hôpital du Sacré Coeur de Montréal, Montreal, Quebec, Canada
    Ann Pharmacother 37:899-904. 2003

Collaborators

Detail Information

Publications10

  1. ncbi Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes
    G J Pearson
    Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
    J Clin Pharm Ther 26:351-61. 2001
    ..The under-utilization and under-dosing of angiotensin-converting enzyme inhibitors (ACEIs) in patients with congestive heart failure (CHF) continues to be a problem observed in clinical practice...
  2. ncbi Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience
    Glen J Pearson
    Department of Medicine, Divisions of Cardiology, Cardiovascular Risk Reduction Clinic, University of Alberta Hospital, Edmonton, Alberta, Canada
    Vasc Health Risk Manag 4:1127-35. 2008
    ..We evaluated the impact of a CRRC on lipid levels and assessed the long-term effect of a CRRC in maintaining improved lipid levels following discharge...
  3. ncbi The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
    Glen J Pearson
    Division of Cardiology, University of Alberta, Edmonton, Canada
    Can J Cardiol 22:939-45. 2006
    ..The effect and tolerability of EZ among patients was evaluated in the clinical setting of a specialty cardiovascular risk reduction clinic at the University of Alberta Hospital, Edmonton, Alberta. patients and..
  4. ncbi Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review
    Dalyce M Zuk
    Department of Medicine, University of Alberta, Edmonton, AB T6G2B7, Canada
    Transplant Rev (Orlando) 23:171-7. 2009
    ..To our knowledge, no systematic review of the pharmacokinetic data in orthotopic heart transplant recipients has been published to date...
  5. ncbi 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    Todd J Anderson
    Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada
    Can J Cardiol 29:151-67. 2013
    ..The goal is to increase the appropriate use of evidence-based cardiovascular disease event risk assessment in the management of dyslipidemia as a fundamental means of reducing global risk in the Canadian population...
  6. ncbi New advances in antirejection therapy
    Michael Chan
    Heart Transplant Program, University of Alberta Hospitals, Edmonton, Alberta, Canada
    Curr Opin Cardiol 22:117-22. 2007
    ..Recent improvement in survival after transplant has been in large part due to continued advancement in antirejection therapies...
  7. ncbi Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
    Taha H Taher
    Department of Medicine, Edmonton, Alberta, Canada
    Am J Cardiol 89:390-4. 2002
    ....
  8. ncbi Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient
    Jeffrey R Burton
    Faculty of Medicine and Dentistry, Division of Cardiology, University of Alberta, Edmonton, AB, Canada
    Ann Pharmacother 41:133-7. 2007
    ....
  9. ncbi Supratherapeutic response to ezetimibe administered with cyclosporine
    Sheri L Koshman
    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Ann Pharmacother 39:1561-5. 2005
    ..Careful and consistent monitoring of patients on this combination is also advised...
  10. ncbi Use of OTC and herbal products in patients with cardiovascular disease
    Chantal Pharand
    Faculty of Pharmacy, Université de Montréal and Hôpital du Sacré Coeur de Montréal, Montreal, Quebec, Canada
    Ann Pharmacother 37:899-904. 2003
    ..The use of nonprescription and herbal products by the public is rising, resulting in an increased potential for adverse reactions or drug interactions in cardiac patients...